ClinicalTrials.gg
TerminatedNCT04200352Updated Apr 22, 2024Results posted

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

A Phase 3 interventional study of TEV-50717 in Cerebral Palsy, Dyskinetic, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Terminated at 30 sites in 9 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Failure of TV50717-CNS-30080 (parent study) to meet the primary efficacy endpoint

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Cerebral Palsy with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Cerebral Palsy · Russian Federation.

Enrollment
13th of 14
44 · median 228
Started
2020
the only one that year
Phase 3
11 of 16
none open now
Registered
14th of 16
by date
Lead sponsor
2 of 16
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 16 studies in Cerebral Palsy with a site in Russian Federation, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2020, is one of 11 in phase 3, and was the 14th registered.

Cerebral Palsy

1,939 studies on the registry are indexed under Cerebral Palsy; 457 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

None of the 16 studies in Cerebral Palsy with a site in Russian Federation is open now. The open studies under Cerebral Palsy, anywhere →

Who these studies take

Of the 269 Cerebral Palsy studies recruiting now, 27 (10%) set no upper age limit and 234 (87%) stop at 75 or younger; 254 take children under 18; 51 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Cerebral Palsy with a site in Russian Federation as a file.
02

Study summary

Study TV50717-CNS-30081 is a 55-week study in which participants who have successfully completed the parent study (Study TV50717-CNS-30080) may be eligible to enroll in this study.

The primary objective of this study is to evaluate the safety and tolerability of long-term therapy with TEV-50717 in children and adolescents with DCP.

The secondary objective of this study is to evaluate the efficacy of long-term therapy with TEV-50717 in reducing the severity of DCP.

03

Conditions studied

  • Cerebral Palsy, Dyskinetic

Browse trials for

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has completed parent Study TV50717-CNS-30080.
  • Participant weighs at least 12 kg (26 lb) on day 1 of this study.
  • Participant is able to swallow TEV-50717 whole. NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Participant has depression at screening or day 1 of this study. Note: Participants receiving antidepressant therapy may be enrolled if on a stable dose for at least 6 weeks before screening or day 1 (whichever comes first) and anticipated to remain stable (dose and frequency) within the study duration.
  • Participant has a history of suicidal intent or related behaviors based on medical or psychiatric history or the C-SSRS at screening visit, if performed, or at the day 1 visit, as applicable according to the participant's age:

    • intent to act on suicidal ideation with a specific plan, irrespective of level of ambivalence, at the time of suicidal thought
    • suicidal preparatory acts or behavior.
  • Participant has a history of a previous actual, interrupted, or aborted suicide attempt.
  • Participant has a first-degree relative who has completed suicide.
  • Participant has received any of the following concomitant Participant has received any of the following concomitant medications within the specified exclusionary windows from screening or day 1 (whichever comes first) of this study:

    • within 30 days: tetrabenazine or valbenazine
    • within 21 days: reserpine
    • within 14 days: levodopa, dopamine agonists, and monoamine oxidase inhibitors
  • Participant has received treatment with stem cells, deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation for treatment of abnormal movements or CP since the week 15 visit of Study TV50717-CNS-30080, or the participant is not in a stable clinical condition.
  • Participants with a history of torsade de pointes, congenital long syndrome, bradyarrhythmias, other cardiac arrhythmias, or uncompensated heart failure.
  • Participant has a known allergy to any of the components of TEV-50717.
  • Participant has participated in an drug or device study other than Study TV50717-CNS-30080 and received IMP/intervention within 30 days or 5 drug half-lives of day 1 of this study, whichever is longer.
  • Participant is pregnant or breastfeeding. NOTE- Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    TEV-50717

    The dose of the TEV-50717 should be increased on a weekly basis to reach a clinically meaningful reduction in dyskinesia, as indicated by a reduction in the Clinical Global Impression of Improvement;(CGI-I).

    Drug: TEV-50717

Interventions

  • DrugTEV-50717

    Oral tablets are 6, 9, and 12 mg.

    Also known as: Deutetrabenazine, SD-809

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Adverse events can include any of the following: clinically significant vital signs, ECG parameters, or laboratory parameters. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.

    Time frame: Baseline up to Week 55

  2. Number of Participants (Aged ≥12 Years) With Columbia-Suicide Severity Rating Scale (C-SSRS) Outcomes (Worst Overall Finding)

    Participants were placed into categories for suicidal ideation or behavior and non-suicidal self-injurious behavior based on their responses to various questions. For suicidal ideation or behavior, the following categories were used: None; Wish to be dead; Non-specific active suicidal thoughts; Any methods (not plan) without intent to act; Some intent to act, without specific plan; Specific plan and intent; Preparatory acts or behavior; Aborted attempt; Interrupted attempt; Actual attempt; and Suicide. For non-suicidal self-injurious behavior, the following categories were used: No or yes. Number of participants with worst overall finding of suicidal ideation or suicidal behavior and non-suicidal self-injurious behavior from Baseline to Week 54 are reported.

    Time frame: Baseline to Week 54

  3. Change From Baseline in Extrapyramidal Symptom Rating Scale (ESRS) Subscale I Total Score at Week 54

    The ESRS subscale I is a 7-item subjective questionnaire to evaluate parkinsonism, akathisia, dystonia and dyskinesia. The ESRS I is scored on a 4-point scale (0=absent, 1=Mild, 2=Moderate, 3=Severe) for each item. The evaluation takes into account the verbal report of the participant on 1) the frequency and duration of the symptom during the day, 2) the number of days the symptom was present during the last week, and 3) the subjective evaluation of the intensity of the symptom by the participant. Total score was the sum of the 7 items which ranges from 0 (absent) to 28 (severe). Higher scores indicate greater severity of disorder.

    Time frame: Baseline, Week 54

  4. Change From Baseline in ESRS Subscale II Total Score at Week 54

    The ESRS subscale II is a 17-item questionnaire to evaluate parkinsonism and akathisia. The ESRS II consists of the following parts: tremor (0 \[none\]-48 \[severe\]), gait and posture (0 \[none\]-6 \[severe\]), postural stability (0 \[none\]-6 \[severe\]), rigidity (0 \[none\]-24 \[severe\]), expressive automatic movements (0 \[none\]-6 \[severe\]), bradykinesia (0 \[none\]-6 \[severe\]), and akathisia (0 \[none\]-6 \[severe\]). Total score was the sum of the 17 items ranging from 0 (absent) to 102 (severe). Higher scores indicate greater severity of disorder.

    Time frame: Baseline, Week 54

  5. Change From Baseline in Child Behavior Checklist (CBCL) Competence Total Score at Week 53

    The CBCL assesses behavioral and emotional status in children ages 6 through 18 years of age as reported by the caregiver. The full CBCL has two parts, a Competence Scale (Parts I to VII) and a Syndrome Scale (behavioral items). The Competence Scale (Parts I to VII) assesses various activities (for example, sports, hobbies, games, organizations, clubs, teams, groups, jobs, and chores), interpersonal relationships, and academic performance. The checklists having 120 questions consist of a number of statements about the child's behavior and responses which are recorded on a scale: 0 = Not True; 1 = Somewhat or Sometimes True; 2 = Very True or Often True. CBCL competence total score ranged from 0 (no problem) to 240 (lesser problem), which was calculated by adding individual scores of each domain. Higher scores indicate greater problems in child behavior.

    Time frame: Baseline, Week 53

  6. Change From Baseline in CBCL Syndrome Total Score at Week 53

    The CBCL assesses behavioral and emotional status in children ages 6 through 18 years of age as reported by the caregiver. The full CBCL has two parts, a Competence Scale (Parts I to VII) and a Syndrome Scale (behavioral items). The Syndrome Scale comprises 113 questions related to problem behaviors. For each item, the responses are recorded on a scale: 0 = Not True; 1 = Somewhat or Sometimes True; 2 = Very True or Often True. The problem behaviors are scored on the following 8 empirically based syndromes: anxious/depressed, withdrawn/depressed, somatic complaints, social problems, thought problems, attention problems, rule-breaking behavior, and aggressive behavior. CBCL syndrome total score ranged from 0 (no problem) to 226 (lesser problem), which was calculated by adding individual scores of each domain. Higher scores indicate greater problems in child behavior.

    Time frame: Baseline, Week 53

  7. Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 54

    The ESS is a self-administered questionnaire composed of 8 questions that provide a measure of a participant's general level of daytime sleepiness. The ESS is composed of 8 items. The responders were asked to rate their chances of falling asleep while engaged at 8 different activities, on a 4-point scale: 0 = would never fall asleep; 1=slight chance of falling asleep; 2=moderate chance of falling asleep; 3=high chance of falling asleep. Total score was calculated as the sum of 8 item scores ranging from 0 (never) to 24 (high chance of falling asleep). Higher scores indicate high chances of falling asleep.

    Time frame: Baseline, Week 54

Secondary outcomes

  1. Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part I Total Score (General Assessment, Centrally Read)

    The MD-CRS part I evaluates the impact of dyskinesia in cerebral palsy (DCP) on the activities of the participant and provides a general assessment of the movement disorder of motor function (7 items), oral/verbal function (3 items), self-care (3 items), and attention/alertness (2 items) on a scale of 0 (present) to 4 (absent). All items were scored by the rater in the clinic and were centrally read based on video recording. The total score was obtained by summing the individual items' scores and ranges from 0 (marked/prolonged disorder) to 60 (absent of a disorder), with higher scores indicating lesser disorder.

    Time frame: Baseline, Week 53, Week 54

  2. Change From Baseline in the MD-CRS Part II Total Score (Movement Disorder Severity, Centrally Read)

    MD-CRS part II evaluates the severity of movement disorder on a scale of 0 to 4 in 7 body regions, all areas in which dyskinesia can be seen. All items were scored by the rater in the clinic and were centrally read based on video recording. In rating the movement disorder of a body part, 0 refers to absence of a movement disorder and 4 refers to a situation where movement disorder is present during all of the tasks for the region examined and/or involves 3 or more of the other regions, making completion impossible. The 7 body regions are (i) eye and periorbital region, (ii) face, (iii) tongue and perioral region, (iv) neck, (v) trunk, (vi) upper limb, and (vii) lower limb. Total score was obtained by summing the individual items scores and ranges from 0 (absent of a movement disorder) to 28 (marked/prolonged movement disorder), with higher scores indicating more movement disorder.

    Time frame: Baseline, Week 53, Week 54

  3. Change From Baseline in the MD-CRS Part I Total Score (General Assessment, Physician Rated)

    The MD-CRS part I evaluates the impact of DCP on the activities of the participant and provides a general assessment of the movement disorder of motor function (7 items), oral/verbal function (3 items), self-care (3 items), and attention/alertness (2 items) on a scale of 0 (present) to 4 (absent). All items were scored by the investigational center physician. The total score was obtained by summing the individual items' scores and ranges from 0 (marked/prolonged movement disorder) to 60 (absent of a movement disorder), with higher scores indicating lesser movement disorder.

    Time frame: Baseline, Week 53, Week 54

  4. Change From Baseline in the MD-CRS Part II Total Score (General Assessment, Physician Rated)

    The MD-CRS part II evaluates the severity of the movement disorder on a scale of 0 to 4 in 7 body regions, all areas in which dyskinesia can be seen in participants with CP. All items were scored by the investigational center physician. In rating the movement disorder of the body part, 0 refers to absence of a movement disorder and 4 refers to a situation where movement disorder is present during all of the tasks for the region examined and/or involves 3 or more of the other regions, making completion impossible. The 7 body regions are (i) eye and periorbital region, (ii) face, (iii) tongue and perioral region, (iv) neck, (v) trunk, (vi) upper limb, and (vii) lower limb. The total score was obtained by summing the individual items' scores and ranges from 0 (absent of a movement disorder) to 28 (marked/prolonged movement disorder), with higher scores indicating more movement disorder.

    Time frame: Baseline, Week 53, Week 54

  5. Change From Baseline in MD-CRS Global Index Score (Calculated From MD-CRS Parts I and II Total Scores, Physician Rated)

    The MD-CRS Global Index is a global measure of the MD-CRS that consolidates the information from parts I and II using the method of weighted means of the 2 normalized indexes obtained from each part. The standardized/normalized score for each item of MD-CRS parts I and II with value X is calculated using the formula: Xst = X - Xmin divided by Xmax - Xmin, where Xmax is the maximum value for the score, and Xmin is the minimum value for the score, or 4 and 0 respectively. The normalized index for the scale, MD-CRS parts I or II, Index I or II, is calculated as the mean value of Xst. The MD-CRS Global Index is the weighted mean of the normalized indexes for centrally read MD-CRS parts I and II using the formula: Global index = n1 \* index 1 + n2 \* index 2 divided by n1 + n2, where n1 and n2 are the numbers of items in MD-CRS parts I and II respectively. The minimum score is 0 (better) and the maximum score is 1 (worse). The higher score indicates more severe movement disorder.

    Time frame: Baseline, Week 53, Week 54

  6. Change From Baseline in MD-CRS Global Index Score (Calculated From MD-CRS Parts I and II Total Scores, Centrally Read)

    The MD-CRS Global Index is a global measure of the MD-CRS that consolidates the information from parts I and II using the method of weighted means of the 2 normalized indexes obtained from each part. The standardized/normalized score for each item of MD-CRS parts I and II with value X is calculated using the formula: Xst = X - Xmin divided by Xmax - Xmin, where Xmax is the maximum value for the score, and Xmin is the minimum value for the score, or 4 and 0 respectively. The normalized index for the scale, MD-CRS parts I or II, Index I or II, is calculated as the mean value of Xst. The MD-CRS Global Index is the weighted mean of the normalized indexes for centrally read MD-CRS parts I and II using the formula: Global index = n1 \* index 1 + n2 \* index 2 divided by n1 + n2, where n1 and n2 are the numbers of items in MD-CRS parts I and II respectively. The minimum score is 0 (better) and the maximum score is 1 (worse). The higher score indicates more severe movement disorder.

    Time frame: Baseline, Week 53, Week 54

  7. Change From Baseline in Caregiver Global Impression of Improvement (CaGI-I) Scale Score (Global, Caregiver Rated) at Week 54

    The CaGI-I is single item questionnaire to assess the caregiver's impression of improvement in dyskinesia symptoms after initiating therapy. The scale is a caregiver-reported outcome that aims to evaluate all aspects of participants' health and determine if there has been an overall improvement or not in dyskinesia symptoms. The caregiver selected the 1 response from the response options that gave the most accurate description of change in dyskinesia symptoms of the participant they cared for from the beginning of the study: 1=very much improved (since the initiation of treatment); 2=much improved; 3=minimally improved; 4=no change from baseline (symptoms remain essentially unchanged); 5=minimally worse; 6=much worse; 7=very much worse (since the initiation of treatment). The change from baseline CaGI-I score can range from -6 to 6.

    Time frame: Baseline, Week 54

  8. Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Scale Score (Global, Physician Rated) at Week 54

    CGI-I is a clinician-reported outcome with a 7-point Likert scale to compare participant's condition to the baseline condition: 1=very much improved since initiation of treatment (nearly all better; good level of functioning; minimal symptoms; represents a very substantial change); 2=much improved (notably better with significant reduction of symptoms; increase in level of functioning but some symptoms remain); 3=minimally improved (slightly better with little or no clinically meaningful reduction of symptoms; represents very little change in basic clinical status, level of care, or functional capacity); 4=no change from baseline (symptoms remain unchanged); 5=minimally worse (slightly worse but may not be clinically meaningful); 6=much worse (clinically significant increase in symptoms and diminished functioning); 7=very much worse since initiation of treatment (severe exacerbation of symptoms and loss of functioning). The change from baseline CGI-I score can range from -6 to 6.

    Time frame: Baseline, Week 54

  9. Change From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score (Global, Physician Rated) at Week 54

    The CGI-S uses a 7-point Likert scale to assess dyskinesia severity as follows (with anchor points for choosing the most appropriate severity level caused by DCP): 1=normal (not at all ill, symptoms of disorder not present past 7 days); 2=borderline (subtle or suspected pathology); 3=mild (clearly established symptoms with minimal, if any, distress or difficulty in social and/or occupational function); 4=moderate (overt symptoms causing noticeable, but modest, functional impairment or distress; symptom level may warrant medication); 5=marked (intrusive symptoms that distinctly impair social/occupational function or cause intrusive levels of distress); 6=severe (disruptive symptoms, behavior, and function are frequently influenced by symptoms, may require assistance from others); 7=extreme (symptoms drastically interfere in many life functions; may be hospitalized). Higher scores indicating more severity.

    Time frame: Baseline, Week 54

  10. Change From Baseline in Pediatric Evaluation Disability Inventory-Computer Adapted Test (PEDI-CAT) Score (Activities of Daily Living [ADL], Caregiver Completed, Content-Balanced Version) at Week 53

    The PEDI-CAT measures function in 4 domains: (1) Daily Activities; (2) Mobility; (3) Social/Cognitive, and (4) Responsibility. The content-balanced version presents a balance of items from each of the Daily Activities domain's content areas (Getting Dressed, Keeping Clean, Home Tasks, and Eating and Mealtime). A total of approximately 30 items were administered. PEDI-CAT software utilizes Item Response Theory statistical models to estimate a child's abilities from a minimal number of the most relevant items or from a set number of items within each domain. The CAT program then displays the results: normative standard scores, scaled scores, and SE. Scaled score is reported in this endpoint. Scaled scores are based on an estimate of the placement of an individual child along the hierarchical scale within each domain. PEDI-CAT scaled scores are currently on a 20 (lesser improvement) to 80 (more improvement) scale metric. Higher scores indicate greater improvement in functional skills.

    Time frame: Baseline, Week 53

  11. Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Chorea (UHDRS-TMC) Score (Centrally Read) at Week 53

    The UHDRS-TMC is part of the Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) assessment and assesses the severity of chorea in the 7 body parts: face, mouth, trunk, and the 4 extremities (right and left upper extremities, right and left lower extremities). Each part was rated from 0 (absent) to 4 (prolonged). The central rating was done for all participants, based on the videos collected for the central rating of MD-CRS. The TMC score was obtained by adding up each of the separate scores and ranged from 0 (absent) to 28 (marked/prolonged), with higher scores indicating the worse symptoms.

    Time frame: Baseline, Week 53

  12. Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Dystonia (UHDRS-TMD) Score (Centrally Read) at Week 53

    The UHDRS-TMD is part of the UHDRS-TMS assessment and assesses the severity of dystonia in the 5 body parts: trunk and the 4 extremities (right and left upper extremities, right and left lower extremities). Each part was rated from 0 (absent) to 4 (prolonged). The central rating was done for all participants, based on the videos collected for the central rating of MD-CRS. The TMD score was obtained by adding up each of the separate scores and ranged from 0 (absent) to 20 (marked/prolonged), with higher scores indicating the worse symptoms.

    Time frame: Baseline, Week 53

  13. Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) Score (Physician Rated) at Week 53

    The UHDRS comprises a broad assessment of features associated with Huntington's disease (HD). It is a research tool that has been developed to provide a uniform assessment of the clinical features and course of HD. The Total Motor Score assessment of the UHDRS (UHDRS-TMS) comprises 15 items and assesses eye movements, speech, alternating hand movements, dystonia, chorea, and gait. The UHDRS-TMS was calculated as the sum of the 31 motor assessments; each of which ranged between 0 (absent) to 4 (worst). All items were scored by the investigational center physician. TMS score is a sum of individual scores ranging from 0 (normal motor function) to 124 (severely impaired motor function), with lower scores indicating better motor function.

    Time frame: Baseline, Week 53

  14. Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Chorea (UHDRS-TMC) Score (Physician Rated) at Week 53

    The UHDRS-TMC is part of the UHDRS-TMS assessment and assesses the severity of chorea in the 7 body parts: face, mouth, trunk, and the 4 extremities (right and left upper extremities, right and left lower extremities). Each part was rated from 0 (absent) to 4 (prolonged). All items were scored by the investigational center physician. The TMC score was obtained by adding up each of the separate scores and ranged from 0 (absent) to 28 (marked/prolonged), with higher scores indicating the worse symptoms.

    Time frame: Baseline, Week 53

  15. Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Dystonia (UHDRS-TMD) Score (Physician Rated) at Week 53

    The UHDRS-TMD is part of the UHDRS-TMS assessment and assesses the severity of dystonia in the 5 body parts: trunk and the 4 extremities (right and left upper extremities, right and left lower extremities). Each part was rated from 0 (absent) to 4 (prolonged). All items were scored by the investigational center physician. The TMD score was obtained by adding up each of the separate scores and ranged from 0 (absent) to 20 (marked/prolonged), with higher scores indicating the worse symptoms.

    Time frame: Baseline, Week 53

  16. Change From Baseline in Canadian Occupational Performance Measure (COPM) (Physician Rated) Score at Week 53

    The COPM, a semi-structured interview, was used to assess a participant's perception of performance in the areas of self-care, productivity and leisure. The COPM involves a 5-step process within a semi-structured interview conducted by a therapist. The participants were asked to rate 5 most important activities on a 10-point scale for performance and satisfaction, ranging from 1 (not at all able/satisfied) to 10 (able to perform extremely well/ extremely satisfied). Total score is the average of the total performance and satisfaction subscales. Each subscale score is calculated by adding the scores of all activities and then dividing by the number of the activities. The total change from baseline scores can range from -9 to 9. Higher scores indicated very good performance and high satisfaction.

    Time frame: Baseline, Week 53

07

Results

Posted Apr 22, 2024
Limitations and caveats
The study was terminated early due to failure of TV50717-CNS-30080 (parent study) to meet the primary efficacy endpoint.

Participant flow

Participant flow — Overall Study
MilestoneTEV-50717
Started44
Received at least 1 dose of study drug44
Completed24
Not completed20
Withdrew: Death1
Withdrew: Adverse event6
Withdrew: Withdrawal by parent/guardian6
Withdrew: Lack of efficacy1
Withdrew: Other than specified6

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

Adverse events can include any of the following: clinically significant vital signs, ECG parameters, or laboratory parameters. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.

Time frame:
Baseline up to Week 55
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsTEV-50717
Number of Participants With Adverse Events (AEs)39
PrimaryNumber of Participants (Aged ≥12 Years) With Columbia-Suicide Severity Rating Scale (C-SSRS) Outcomes (Worst Overall Finding)

Participants were placed into categories for suicidal ideation or behavior and non-suicidal self-injurious behavior based on their responses to various questions. For suicidal ideation or behavior, the following categories were used: None; Wish to be dead; Non-specific active suicidal thoughts; Any methods (not plan) without intent to act; Some intent to act, without specific plan; Specific plan and intent; Preparatory acts or behavior; Aborted attempt; Interrupted attempt; Actual attempt; and Suicide. For non-suicidal self-injurious behavior, the following categories were used: No or yes. Number of participants with worst overall finding of suicidal ideation or suicidal behavior and non-suicidal self-injurious behavior from Baseline to Week 54 are reported.

Time frame:
Baseline to Week 54
Reported as:
Count of participants · Participants
Number of Participants (Aged ≥12 Years) With Columbia-Suicide Severity Rating Scale (C-SSRS) Outcomes (Worst Overall Finding)
ParticipantsTEV-50717
Suicidal ideation/behavior - None18
Suicidal ideation/behavior - Wish to be dead0
Suicidal ideation/behavior - Non-specific active suicidal thoughts0
Suicidal ideation/behavior - Any methods (not plan) without intent to act0
Suicidal ideation/behavior - Some intent to act, without specific plan0
Suicidal ideation/behavior - Specific plan and intent0
Suicidal ideation/behavior - Preparatory acts or behavior0
Suicidal ideation/behavior - Aborted attempt0
Suicidal ideation/behavior - Interrupted attempt0
Suicidal ideation/behavior - Actual attempt0
Suicidal ideation/behavior - Suicide0
Non-suicidal self-injurious behavior - No18
Non-suicidal self-injurious behavior - Yes0
PrimaryChange From Baseline in Extrapyramidal Symptom Rating Scale (ESRS) Subscale I Total Score at Week 54

The ESRS subscale I is a 7-item subjective questionnaire to evaluate parkinsonism, akathisia, dystonia and dyskinesia. The ESRS I is scored on a 4-point scale (0=absent, 1=Mild, 2=Moderate, 3=Severe) for each item. The evaluation takes into account the verbal report of the participant on 1) the frequency and duration of the symptom during the day, 2) the number of days the symptom was present during the last week, and 3) the subjective evaluation of the intensity of the symptom by the participant. Total score was the sum of the 7 items which ranges from 0 (absent) to 28 (severe). Higher scores indicate greater severity of disorder.

Time frame:
Baseline, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in Extrapyramidal Symptom Rating Scale (ESRS) Subscale I Total Score at Week 54
units on a scaleTEV-50717
Change From Baseline in Extrapyramidal Symptom Rating Scale (ESRS) Subscale I Total Score at Week 54-1.4 ± 2.02
PrimaryChange From Baseline in ESRS Subscale II Total Score at Week 54

The ESRS subscale II is a 17-item questionnaire to evaluate parkinsonism and akathisia. The ESRS II consists of the following parts: tremor (0 \[none\]-48 \[severe\]), gait and posture (0 \[none\]-6 \[severe\]), postural stability (0 \[none\]-6 \[severe\]), rigidity (0 \[none\]-24 \[severe\]), expressive automatic movements (0 \[none\]-6 \[severe\]), bradykinesia (0 \[none\]-6 \[severe\]), and akathisia (0 \[none\]-6 \[severe\]). Total score was the sum of the 17 items ranging from 0 (absent) to 102 (severe). Higher scores indicate greater severity of disorder.

Time frame:
Baseline, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in ESRS Subscale II Total Score at Week 54
units on a scaleTEV-50717
Change From Baseline in ESRS Subscale II Total Score at Week 54-1.5 ± 6.41
PrimaryChange From Baseline in Child Behavior Checklist (CBCL) Competence Total Score at Week 53

The CBCL assesses behavioral and emotional status in children ages 6 through 18 years of age as reported by the caregiver. The full CBCL has two parts, a Competence Scale (Parts I to VII) and a Syndrome Scale (behavioral items). The Competence Scale (Parts I to VII) assesses various activities (for example, sports, hobbies, games, organizations, clubs, teams, groups, jobs, and chores), interpersonal relationships, and academic performance. The checklists having 120 questions consist of a number of statements about the child's behavior and responses which are recorded on a scale: 0 = Not True; 1 = Somewhat or Sometimes True; 2 = Very True or Often True. CBCL competence total score ranged from 0 (no problem) to 240 (lesser problem), which was calculated by adding individual scores of each domain. Higher scores indicate greater problems in child behavior.

Time frame:
Baseline, Week 53
Reported as:
Mean · units on a scale
Change From Baseline in Child Behavior Checklist (CBCL) Competence Total Score at Week 53
units on a scaleTEV-50717
Change From Baseline in Child Behavior Checklist (CBCL) Competence Total Score at Week 530.49 ± 3.018
PrimaryChange From Baseline in CBCL Syndrome Total Score at Week 53

The CBCL assesses behavioral and emotional status in children ages 6 through 18 years of age as reported by the caregiver. The full CBCL has two parts, a Competence Scale (Parts I to VII) and a Syndrome Scale (behavioral items). The Syndrome Scale comprises 113 questions related to problem behaviors. For each item, the responses are recorded on a scale: 0 = Not True; 1 = Somewhat or Sometimes True; 2 = Very True or Often True. The problem behaviors are scored on the following 8 empirically based syndromes: anxious/depressed, withdrawn/depressed, somatic complaints, social problems, thought problems, attention problems, rule-breaking behavior, and aggressive behavior. CBCL syndrome total score ranged from 0 (no problem) to 226 (lesser problem), which was calculated by adding individual scores of each domain. Higher scores indicate greater problems in child behavior.

Time frame:
Baseline, Week 53
Reported as:
Mean · units on a scale
Change From Baseline in CBCL Syndrome Total Score at Week 53
units on a scaleTEV-50717
Change From Baseline in CBCL Syndrome Total Score at Week 53-1.7 ± 14.96
PrimaryChange From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 54

The ESS is a self-administered questionnaire composed of 8 questions that provide a measure of a participant's general level of daytime sleepiness. The ESS is composed of 8 items. The responders were asked to rate their chances of falling asleep while engaged at 8 different activities, on a 4-point scale: 0 = would never fall asleep; 1=slight chance of falling asleep; 2=moderate chance of falling asleep; 3=high chance of falling asleep. Total score was calculated as the sum of 8 item scores ranging from 0 (never) to 24 (high chance of falling asleep). Higher scores indicate high chances of falling asleep.

Time frame:
Baseline, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 54
units on a scaleTEV-50717
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 540.7 ± 3.51
SecondaryChange From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part I Total Score (General Assessment, Centrally Read)

The MD-CRS part I evaluates the impact of dyskinesia in cerebral palsy (DCP) on the activities of the participant and provides a general assessment of the movement disorder of motor function (7 items), oral/verbal function (3 items), self-care (3 items), and attention/alertness (2 items) on a scale of 0 (present) to 4 (absent). All items were scored by the rater in the clinic and were centrally read based on video recording. The total score was obtained by summing the individual items' scores and ranges from 0 (marked/prolonged disorder) to 60 (absent of a disorder), with higher scores indicating lesser disorder.

Time frame:
Baseline, Week 53, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part I Total Score (General Assessment, Centrally Read)
units on a scaleTEV-50717
Change at Week 53-2.41 ± 5.24
Change at Week 54-1.40 ± 4.989
SecondaryChange From Baseline in the MD-CRS Part II Total Score (Movement Disorder Severity, Centrally Read)

MD-CRS part II evaluates the severity of movement disorder on a scale of 0 to 4 in 7 body regions, all areas in which dyskinesia can be seen. All items were scored by the rater in the clinic and were centrally read based on video recording. In rating the movement disorder of a body part, 0 refers to absence of a movement disorder and 4 refers to a situation where movement disorder is present during all of the tasks for the region examined and/or involves 3 or more of the other regions, making completion impossible. The 7 body regions are (i) eye and periorbital region, (ii) face, (iii) tongue and perioral region, (iv) neck, (v) trunk, (vi) upper limb, and (vii) lower limb. Total score was obtained by summing the individual items scores and ranges from 0 (absent of a movement disorder) to 28 (marked/prolonged movement disorder), with higher scores indicating more movement disorder.

Time frame:
Baseline, Week 53, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in the MD-CRS Part II Total Score (Movement Disorder Severity, Centrally Read)
units on a scaleTEV-50717
Change at Week 53-1.5 ± 3.91
Change at Week 540.5 ± 4.34
SecondaryChange From Baseline in the MD-CRS Part I Total Score (General Assessment, Physician Rated)

The MD-CRS part I evaluates the impact of DCP on the activities of the participant and provides a general assessment of the movement disorder of motor function (7 items), oral/verbal function (3 items), self-care (3 items), and attention/alertness (2 items) on a scale of 0 (present) to 4 (absent). All items were scored by the investigational center physician. The total score was obtained by summing the individual items' scores and ranges from 0 (marked/prolonged movement disorder) to 60 (absent of a movement disorder), with higher scores indicating lesser movement disorder.

Time frame:
Baseline, Week 53, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in the MD-CRS Part I Total Score (General Assessment, Physician Rated)
units on a scaleTEV-50717
Change at Week 53-2.6 ± 3.70
Change at Week 54-1.4 ± 3.72
SecondaryChange From Baseline in the MD-CRS Part II Total Score (General Assessment, Physician Rated)

The MD-CRS part II evaluates the severity of the movement disorder on a scale of 0 to 4 in 7 body regions, all areas in which dyskinesia can be seen in participants with CP. All items were scored by the investigational center physician. In rating the movement disorder of the body part, 0 refers to absence of a movement disorder and 4 refers to a situation where movement disorder is present during all of the tasks for the region examined and/or involves 3 or more of the other regions, making completion impossible. The 7 body regions are (i) eye and periorbital region, (ii) face, (iii) tongue and perioral region, (iv) neck, (v) trunk, (vi) upper limb, and (vii) lower limb. The total score was obtained by summing the individual items' scores and ranges from 0 (absent of a movement disorder) to 28 (marked/prolonged movement disorder), with higher scores indicating more movement disorder.

Time frame:
Baseline, Week 53, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in the MD-CRS Part II Total Score (General Assessment, Physician Rated)
units on a scaleTEV-50717
Change at Week 53-3.12 ± 4.255
Change at Week 54-1.88 ± 3.927
SecondaryChange From Baseline in MD-CRS Global Index Score (Calculated From MD-CRS Parts I and II Total Scores, Physician Rated)

The MD-CRS Global Index is a global measure of the MD-CRS that consolidates the information from parts I and II using the method of weighted means of the 2 normalized indexes obtained from each part. The standardized/normalized score for each item of MD-CRS parts I and II with value X is calculated using the formula: Xst = X - Xmin divided by Xmax - Xmin, where Xmax is the maximum value for the score, and Xmin is the minimum value for the score, or 4 and 0 respectively. The normalized index for the scale, MD-CRS parts I or II, Index I or II, is calculated as the mean value of Xst. The MD-CRS Global Index is the weighted mean of the normalized indexes for centrally read MD-CRS parts I and II using the formula: Global index = n1 \* index 1 + n2 \* index 2 divided by n1 + n2, where n1 and n2 are the numbers of items in MD-CRS parts I and II respectively. The minimum score is 0 (better) and the maximum score is 1 (worse). The higher score indicates more severe movement disorder.

Time frame:
Baseline, Week 53, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in MD-CRS Global Index Score (Calculated From MD-CRS Parts I and II Total Scores, Physician Rated)
units on a scaleTEV-50717
Change at Week 53-0.1 ± 0.07
Change at Week 54-0.0 ± 0.07
SecondaryChange From Baseline in MD-CRS Global Index Score (Calculated From MD-CRS Parts I and II Total Scores, Centrally Read)

The MD-CRS Global Index is a global measure of the MD-CRS that consolidates the information from parts I and II using the method of weighted means of the 2 normalized indexes obtained from each part. The standardized/normalized score for each item of MD-CRS parts I and II with value X is calculated using the formula: Xst = X - Xmin divided by Xmax - Xmin, where Xmax is the maximum value for the score, and Xmin is the minimum value for the score, or 4 and 0 respectively. The normalized index for the scale, MD-CRS parts I or II, Index I or II, is calculated as the mean value of Xst. The MD-CRS Global Index is the weighted mean of the normalized indexes for centrally read MD-CRS parts I and II using the formula: Global index = n1 \* index 1 + n2 \* index 2 divided by n1 + n2, where n1 and n2 are the numbers of items in MD-CRS parts I and II respectively. The minimum score is 0 (better) and the maximum score is 1 (worse). The higher score indicates more severe movement disorder.

Time frame:
Baseline, Week 53, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in MD-CRS Global Index Score (Calculated From MD-CRS Parts I and II Total Scores, Centrally Read)
units on a scaleTEV-50717
Change at Week 53-0.0 ± 0.08
Change at Week 54-0.0 ± 0.06
SecondaryChange From Baseline in Caregiver Global Impression of Improvement (CaGI-I) Scale Score (Global, Caregiver Rated) at Week 54

The CaGI-I is single item questionnaire to assess the caregiver's impression of improvement in dyskinesia symptoms after initiating therapy. The scale is a caregiver-reported outcome that aims to evaluate all aspects of participants' health and determine if there has been an overall improvement or not in dyskinesia symptoms. The caregiver selected the 1 response from the response options that gave the most accurate description of change in dyskinesia symptoms of the participant they cared for from the beginning of the study: 1=very much improved (since the initiation of treatment); 2=much improved; 3=minimally improved; 4=no change from baseline (symptoms remain essentially unchanged); 5=minimally worse; 6=much worse; 7=very much worse (since the initiation of treatment). The change from baseline CaGI-I score can range from -6 to 6.

Time frame:
Baseline, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in Caregiver Global Impression of Improvement (CaGI-I) Scale Score (Global, Caregiver Rated) at Week 54
units on a scaleTEV-50717
Change From Baseline in Caregiver Global Impression of Improvement (CaGI-I) Scale Score (Global, Caregiver Rated) at Week 54-0.6 ± 1.20
SecondaryChange From Baseline in Clinical Global Impression of Improvement (CGI-I) Scale Score (Global, Physician Rated) at Week 54

CGI-I is a clinician-reported outcome with a 7-point Likert scale to compare participant's condition to the baseline condition: 1=very much improved since initiation of treatment (nearly all better; good level of functioning; minimal symptoms; represents a very substantial change); 2=much improved (notably better with significant reduction of symptoms; increase in level of functioning but some symptoms remain); 3=minimally improved (slightly better with little or no clinically meaningful reduction of symptoms; represents very little change in basic clinical status, level of care, or functional capacity); 4=no change from baseline (symptoms remain unchanged); 5=minimally worse (slightly worse but may not be clinically meaningful); 6=much worse (clinically significant increase in symptoms and diminished functioning); 7=very much worse since initiation of treatment (severe exacerbation of symptoms and loss of functioning). The change from baseline CGI-I score can range from -6 to 6.

Time frame:
Baseline, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Scale Score (Global, Physician Rated) at Week 54
units on a scaleTEV-50717
Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Scale Score (Global, Physician Rated) at Week 54-0.2 ± 0.88
SecondaryChange From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score (Global, Physician Rated) at Week 54

The CGI-S uses a 7-point Likert scale to assess dyskinesia severity as follows (with anchor points for choosing the most appropriate severity level caused by DCP): 1=normal (not at all ill, symptoms of disorder not present past 7 days); 2=borderline (subtle or suspected pathology); 3=mild (clearly established symptoms with minimal, if any, distress or difficulty in social and/or occupational function); 4=moderate (overt symptoms causing noticeable, but modest, functional impairment or distress; symptom level may warrant medication); 5=marked (intrusive symptoms that distinctly impair social/occupational function or cause intrusive levels of distress); 6=severe (disruptive symptoms, behavior, and function are frequently influenced by symptoms, may require assistance from others); 7=extreme (symptoms drastically interfere in many life functions; may be hospitalized). Higher scores indicating more severity.

Time frame:
Baseline, Week 54
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score (Global, Physician Rated) at Week 54
units on a scaleTEV-50717
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Scale Score (Global, Physician Rated) at Week 54-0.3 ± 0.64
SecondaryChange From Baseline in Pediatric Evaluation Disability Inventory-Computer Adapted Test (PEDI-CAT) Score (Activities of Daily Living [ADL], Caregiver Completed, Content-Balanced Version) at Week 53

The PEDI-CAT measures function in 4 domains: (1) Daily Activities; (2) Mobility; (3) Social/Cognitive, and (4) Responsibility. The content-balanced version presents a balance of items from each of the Daily Activities domain's content areas (Getting Dressed, Keeping Clean, Home Tasks, and Eating and Mealtime). A total of approximately 30 items were administered. PEDI-CAT software utilizes Item Response Theory statistical models to estimate a child's abilities from a minimal number of the most relevant items or from a set number of items within each domain. The CAT program then displays the results: normative standard scores, scaled scores, and SE. Scaled score is reported in this endpoint. Scaled scores are based on an estimate of the placement of an individual child along the hierarchical scale within each domain. PEDI-CAT scaled scores are currently on a 20 (lesser improvement) to 80 (more improvement) scale metric. Higher scores indicate greater improvement in functional skills.

Time frame:
Baseline, Week 53
Reported as:
Mean · units on a scale
Change From Baseline in Pediatric Evaluation Disability Inventory-Computer Adapted Test (PEDI-CAT) Score (Activities of Daily Living [ADL], Caregiver Completed, Content-Balanced Version) at Week 53
units on a scaleTEV-50717
Change From Baseline in Pediatric Evaluation Disability Inventory-Computer Adapted Test (PEDI-CAT) Score (Activities of Daily Living [ADL], Caregiver Completed, Content-Balanced Version) at Week 530.9 ± 2.39
SecondaryChange From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Chorea (UHDRS-TMC) Score (Centrally Read) at Week 53

The UHDRS-TMC is part of the Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) assessment and assesses the severity of chorea in the 7 body parts: face, mouth, trunk, and the 4 extremities (right and left upper extremities, right and left lower extremities). Each part was rated from 0 (absent) to 4 (prolonged). The central rating was done for all participants, based on the videos collected for the central rating of MD-CRS. The TMC score was obtained by adding up each of the separate scores and ranged from 0 (absent) to 28 (marked/prolonged), with higher scores indicating the worse symptoms.

Time frame:
Baseline, Week 53
Reported as:
Mean · units on a scale
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Chorea (UHDRS-TMC) Score (Centrally Read) at Week 53
units on a scaleTEV-50717
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Chorea (UHDRS-TMC) Score (Centrally Read) at Week 530.0 ± 3.20
SecondaryChange From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Dystonia (UHDRS-TMD) Score (Centrally Read) at Week 53

The UHDRS-TMD is part of the UHDRS-TMS assessment and assesses the severity of dystonia in the 5 body parts: trunk and the 4 extremities (right and left upper extremities, right and left lower extremities). Each part was rated from 0 (absent) to 4 (prolonged). The central rating was done for all participants, based on the videos collected for the central rating of MD-CRS. The TMD score was obtained by adding up each of the separate scores and ranged from 0 (absent) to 20 (marked/prolonged), with higher scores indicating the worse symptoms.

Time frame:
Baseline, Week 53
Reported as:
Mean · units on a scale
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Dystonia (UHDRS-TMD) Score (Centrally Read) at Week 53
units on a scaleTEV-50717
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Dystonia (UHDRS-TMD) Score (Centrally Read) at Week 53-1.0 ± 3.38
SecondaryChange From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) Score (Physician Rated) at Week 53

The UHDRS comprises a broad assessment of features associated with Huntington's disease (HD). It is a research tool that has been developed to provide a uniform assessment of the clinical features and course of HD. The Total Motor Score assessment of the UHDRS (UHDRS-TMS) comprises 15 items and assesses eye movements, speech, alternating hand movements, dystonia, chorea, and gait. The UHDRS-TMS was calculated as the sum of the 31 motor assessments; each of which ranged between 0 (absent) to 4 (worst). All items were scored by the investigational center physician. TMS score is a sum of individual scores ranging from 0 (normal motor function) to 124 (severely impaired motor function), with lower scores indicating better motor function.

Time frame:
Baseline, Week 53
Reported as:
Mean · units on a scale
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) Score (Physician Rated) at Week 53
units on a scaleTEV-50717
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) Score (Physician Rated) at Week 53-7.8 ± 7.78
SecondaryChange From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Chorea (UHDRS-TMC) Score (Physician Rated) at Week 53

The UHDRS-TMC is part of the UHDRS-TMS assessment and assesses the severity of chorea in the 7 body parts: face, mouth, trunk, and the 4 extremities (right and left upper extremities, right and left lower extremities). Each part was rated from 0 (absent) to 4 (prolonged). All items were scored by the investigational center physician. The TMC score was obtained by adding up each of the separate scores and ranged from 0 (absent) to 28 (marked/prolonged), with higher scores indicating the worse symptoms.

Time frame:
Baseline, Week 53
Reported as:
Mean · units on a scale
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Chorea (UHDRS-TMC) Score (Physician Rated) at Week 53
units on a scaleTEV-50717
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Chorea (UHDRS-TMC) Score (Physician Rated) at Week 53-3.9 ± 4.50
SecondaryChange From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Dystonia (UHDRS-TMD) Score (Physician Rated) at Week 53

The UHDRS-TMD is part of the UHDRS-TMS assessment and assesses the severity of dystonia in the 5 body parts: trunk and the 4 extremities (right and left upper extremities, right and left lower extremities). Each part was rated from 0 (absent) to 4 (prolonged). All items were scored by the investigational center physician. The TMD score was obtained by adding up each of the separate scores and ranged from 0 (absent) to 20 (marked/prolonged), with higher scores indicating the worse symptoms.

Time frame:
Baseline, Week 53
Reported as:
Mean · units on a scale
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Dystonia (UHDRS-TMD) Score (Physician Rated) at Week 53
units on a scaleTEV-50717
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Maximal Dystonia (UHDRS-TMD) Score (Physician Rated) at Week 53-0.9 ± 1.65
SecondaryChange From Baseline in Canadian Occupational Performance Measure (COPM) (Physician Rated) Score at Week 53

The COPM, a semi-structured interview, was used to assess a participant's perception of performance in the areas of self-care, productivity and leisure. The COPM involves a 5-step process within a semi-structured interview conducted by a therapist. The participants were asked to rate 5 most important activities on a 10-point scale for performance and satisfaction, ranging from 1 (not at all able/satisfied) to 10 (able to perform extremely well/ extremely satisfied). Total score is the average of the total performance and satisfaction subscales. Each subscale score is calculated by adding the scores of all activities and then dividing by the number of the activities. The total change from baseline scores can range from -9 to 9. Higher scores indicated very good performance and high satisfaction.

Time frame:
Baseline, Week 53
Reported as:
Mean · units on a scale
Change From Baseline in Canadian Occupational Performance Measure (COPM) (Physician Rated) Score at Week 53
units on a scaleTEV-50717
Change From Baseline in Canadian Occupational Performance Measure (COPM) (Physician Rated) Score at Week 531.4 ± 1.36

Adverse events

Collected over Baseline up to Week 55. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TEV-507171/44 (2.3%)1/44 (2.3%)33/44 (75%)
Most frequent serious events
Most frequent serious events
EventTEV-50717
Cardiopulmonary failureCardiac disorders1/44
COVID-19Infections and infestations1/44
SeizureNervous system disorders1/44
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTEV-50717
SomnolenceNervous system disorders21/44
DiarrhoeaGastrointestinal disorders4/44
VomitingGastrointestinal disorders4/44
COVID-19Infections and infestations4/44
Abdominal painGastrointestinal disorders3/44
ConstipationGastrointestinal disorders3/44
FatigueGeneral disorders3/44
PyrexiaGeneral disorders3/44
Upper respiratory tract infectionInfections and infestations3/44
AkathisiaNervous system disorders3/44

Baseline characteristics

The intent-to-treat (ITT) analysis set included all enrolled participants, regardless of whether or not a participant took any TEV-50717.

Age, Continuous
Age, Continuous(years)TEV-50717
Mean11.1 ± 3.56
Sex: Female, Male
Sex: Female, Male(Participants)TEV-50717
Female15
Male29
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TEV-50717
Hispanic or Latino2
Not Hispanic or Latino39
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TEV-50717
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White42
More than one race0
Unknown or Not Reported2
Extrapyramidal Symptom Rating Scale (ESRS) Subscale I Total Score
Extrapyramidal Symptom Rating Scale (ESRS) Subscale I Total Score(units on a scale)TEV-50717
Mean9.7 ± 3.94
ESRS Subscale II Total Score
ESRS Subscale II Total Score(units on a scale)TEV-50717
Mean20.7 ± 19.73
Child Behavior Checklist (CBCL) Competence Total Score
Child Behavior Checklist (CBCL) Competence Total Score(units on a scale)TEV-50717
Mean11.70 ± 4.392
CBCL Syndrome Total Score
CBCL Syndrome Total Score(units on a scale)TEV-50717
Mean30.7 ± 21.06

1 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Teva Investigational Site 14137
    Birmingham, Alabama 35233, United States
  • Teva Investigational Site 14295
    San Diego, California 92123, United States
  • Teva Investigational Site 14122
    Voorhees, New Jersey 08043, United States
  • Teva Investigational Site 14299
    Charleston, South Carolina 29414, United States
  • Teva Investigational Site 14129
    Nashville, Tennessee 37232, United States
  • Teva Investigational Site 39058
    Blegdamsvej 9, 2100, Denmark
  • Teva Investigational Site 80146
    Tel-Aviv, Tel-Aviv District, 64239, Israel
  • Teva Investigational Site 80147
    Zerifin, Central District, 70300, Israel
  • Teva Investigational Site 30214
    Milan, 20133, Italy
  • Teva Investigational Site 30216
    Pisa, 56018, Italy
  • Teva Investigational Site 53428
    Gdansk, Pomerania Province, 80-389, Poland
  • Teva Investigational Site 53434
    Gdansk, 80-952, Poland
  • Teva Investigational Site 53427
    Krakow, 30-534, Poland
  • Teva Investigational Site 53430
    Wiazowna, Mazovia Province, 05-462, Poland
  • Teva Investigational Site 50477
    Kazan, 420021, Russian Federation
  • Teva Investigational Site 50475
    Khabarovsk, Khabarovsk Krai Region, 680013, Russian Federation
  • Teva Investigational Site 50470
    Moscow, Moscow Region, 129110, Russian Federation
  • Teva Investigational Site 50485
    Nizhniy Novgorod, Nizhny Novgorod Region, 603126, Russian Federation
  • Teva Investigational Site 50468
    Novosibirsk, Novosibirsk Region, 630047, Russian Federation
  • Teva Investigational Site 50469
    Smolensk, Smolensk Region, 214018, Russian Federation
  • Teva Investigational Site 50478
    Stavropol, Stavropol Krai Region, 355000, Russian Federation
  • Teva Investigational Site 50474
    Tyumen, Tyumen Region, 625023, Russian Federation
  • Teva Investigational Site 31254
    Valencia, 46026, Spain
  • Teva Investigational Site 58313
    Dnipro, Dnipropetrovsk Province, 49101, Ukraine
  • Teva Investigational Site 58309
    Kyiv, Kyiv Province, 04209, Ukraine
  • Teva Investigational Site 58311
    Odessa, Odessa Province, 65012, Ukraine
  • Teva Investigational Site 58310
    Vinnytsya, Vinnytsia Province, 21005, Ukraine
  • Teva Investigational Site 34245
    Edinburgh, Edinburgh, EH16 4TJ, United Kingdom
  • Teva Investigational Site 34243
    London, Greater London, SE1 7EH, United Kingdom
  • Teva Investigational Site 34244
    Sheffield, South Yorkshire, S10 2TH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Feb 2023, 36 months.

Results were first posted in Apr 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2019
First posted
Dec 16, 2019
StartActual
Feb 4, 2020
Primary completionActual
Feb 14, 2023
CompletionActual
Feb 14, 2023
Results first posted
Apr 22, 2024
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04200352
Responsible party
Sponsor
First posted
Dec 16, 2019
Start date
Feb 4, 2020
Primary completion
Feb 14, 2023
Completion
Feb 14, 2023
Results posted
Apr 22, 2024
Last update
Apr 22, 2024

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion